Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster

Thorax

Volumn 64, Issue 4, 2009, Pages 345-352

  Forton, J T ^a,b,d   Rowlands, K ^a   Rockett, K ^a   Hanchard, N ^a   Herbert, M ^b   Kwiatkowski, D P ^a,b,c   Hull, J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; CYTOKINE;

ARTICLE; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INFANCY; INFANT; MAJOR CLINICAL STUDY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL BRONCHIOLITIS; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; GENETICS; GENOTYPE; VIRUS INFECTION;

BRONCHIOLITIS, VIRAL; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; CYTOKINES; GENOTYPE; HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 64849105334     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.102111     Document Type: Article

References (34)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, updated 2006. Bethesda, MD: National Heart, Lung and Blood Institute, 2006.
2. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-9.
3. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-64.
4. Makita H, Nasuhara Y, Nagai K, et al. Characterization of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007;62:932-7.
5. Lehmann S, Bakke PS, Eide GE, et al. Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonist. Pulm Pharmacol Ther 2006;19:272-80.
6. Hizawa N, Makita H, Nasuhara Y, et al. b-adrergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007;132:1485-92.
7. Barnes PJ. The role of anticholinergics in chronic obstructive lung disease. Am J Med 2004;117:24-32S.
8. Hasegawa M, Nasuhara Y, Onodera Y, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:1309-15.
9. van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000;55:289-94.
10. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
11. Committee of Pulmonary Physiology, Japanese Respiratory Society. Guidelines for pulmonary function tests: spirometry, flow-volume curve, diffusion capacity of the lung. The Japanese Respiratory Society; Tokyo, 2004 (in Japanese).
12. Anzueto A, Tashkin D, Menjoge S, et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005;18:75-81.
13. Barnes PJ. Theoretical aspects of anticholinergic treatment. In: Gross NJ, ed. Anticholinergic therapy in obstructive airway disease. London: Franklin Scientific Publications, 1993:88-104.
14. Bates DV, Macklem PT, Christie RV. The anatomy of the lung. In: Bates DV, Macklem PT, Christie RV. Respiratory function in disease. Philadelphia: W B Saunders, 1971:1-9.
15. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31:742-50.
16. Brown RH, Herold CJ, Hirshman CA, et al. In vivo measurements of airway reactivity using high-resolution computed tomography. Am Rev Respir Dis 1991;144:208-12.
17. Brown RH, Croisille P, Mudge B, et al. Airway narrowing in healthy humans inhaling methacholine without deep inspirations demonstrated by HRCT. Am J Respir Crit Care Med 2000;161:1256-63.
18. Brown RH, Scichilone N, Mudge B, et al. High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma. Am J Respir Crit Care Med 2001;163:994-1001.
19. Okazawa M, Muller N, McNamara AE, et al. Human airway narrowing measured using high resolution computed tomography. Am J Respir Crit Care Med 1996;154:1557-62.
20. King GG, Carroll JD, Muller NL, et al. Heterogeneity of narrowing in normal and asthmatic airways measured by HRCT. Eur Respir J 2004;24:211-8.
21. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968;278:1355- 60.
22. Van Brabandt H, Cauberghs M, Verbeken E, et al. Partitioning of pulmonary impedance in excised human and canine lungs. J Appl Physiol 1983;55:1733-42.
23. Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992;72:1016-23.
24. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
25. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21.
26. Hensley MJ, O'Cain CF, McFadden ER Jr, et al. Distribution of bronchodilatation in normal subjects: beta agonist versus atropine. J Appl Physiol 1978;45:778-82.
27. Partridge MR, Sauders KB. Site of action of ipratropium bromide and clinical and physiological determinants of response in patients with asthma. Thorax 1981;36:530-3.
28. Ingram RH, Wellman JJ, McFadden ER, et al. Relative contributions of large and small airways to flow limitation in normal subjects before and after atropine and isoproterenol. J Clin Invest 1977;559:696-703.
29. Ohrui T, Yanai M, Sekizawa K, et al. Effective site of bronchodilation by betaadrenergic and anticholinergic agents in patients with chronic obstructive pulmonary disease: direct measurement of intrabronchial pressure with a new catheter. Am Rev Respir Dis 1992;146:88-91.
30. DeTroyer A, Yernault JC, Rodenstein D. Effects of vagal blockade on lung mechanics in normal man. J Appl Physiol 1979;46:217-26.
31. Douglas NJ, Sudlow MF, Flenley DC. Effect of an inhaled atropine-like agent on normal airway function. J Appl Physiol 1979;46:256-62.
32. Stoel BC, Vrooman HA, Stolk J, et al. Sources of error in lung densitometry with CT. Invest Radiol 1999;34:303-9.
33. Parr DJ, Stoel BC, Stolk J, et al. Influence of calibration on densitometric studies of emphysema progression using computed tomography. Am J Respir Crit Care Med 2004;170:883-90.
34. Yuan R, Mayo JR, Hogg JC, et al. The effects of radiation dose and CT manufacturer on measurements of lung densitometry. Chest 2007;132:617-23.